Flag of the European Union EU Clinical Trials Register Help

Clinical trials for 1

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    39,320 result(s) found for: 1. Displaying page 1 of 1,966.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-005055-23 Sponsor Protocol Number: ENDO-002/08 Start Date*: 2009-03-05
    Sponsor Name:OSPEDALE MAGGIORE DI MILANO (IRCCS)
    Full Title: TREATMENT OF HYPERPARATHYROIDISM IN PATIENTS WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 (MEN1) WITH THE CALCIMIMETIC AGENT CINACALCET
    Medical condition: Primary hyperparathyroidism in patients affected with multiple endocrine neoplasia syndrome type 1 (MEN1)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027180 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005996-11 Sponsor Protocol Number: MK-1654-007 Start Date*: 2021-08-26
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for S...
    Medical condition: Prevention of Respiratory syncytial virus (RSV) infection in infants and children at increased risk for severe RSV disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10066742 Respiratory syncytial virus infection prophylaxis LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) Outside EU/EEA HU (Trial now transitioned) FR (Trial now transitioned) NO (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005608-20 Sponsor Protocol Number: D1346C00004 Start Date*: 2021-11-24
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase I/II, Single-Arm, Open label Study to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥ 1 to < 7 Years with Neurofibr...
    Medical condition: Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10029270 Neurofibromatosis, type 1 (von Recklinghausen's disease) LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) NL (Prematurely Ended) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001030-16 Sponsor Protocol Number: V102_16E1 Start Date*: 2016-04-28
    Sponsor Name:Novartis Vaccines and Diagnostics Inc.
    Full Title: A Phase 2b, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of the 3rd Dose of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Ado...
    Medical condition: Novartis Meningococcal ABCWY conjugate vaccine is intended for prevention of meningitis and septicemia caused by Neisseria meningitidis serogroups A, B, C, W and Y.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-000926-23 Sponsor Protocol Number: B1851178 Start Date*: 2024-03-07
    Sponsor Name:Pfizer, Inc.
    Full Title: A PHASE 3 OPEN-LABEL TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN INFANTS AND YOUNG CHILDREN IN CHINA WHO ARE NAIVE TO PNEUMOCOCCAL V...
    Medical condition: Pneumococcal Infections
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-004435-31 Sponsor Protocol Number: MVC116278 Start Date*: 2012-05-15
    Sponsor Name:ViiV Healthcare UK Limited
    Full Title: An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc.
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-006009-18 Sponsor Protocol Number: TMC278-TiDP15-C221 Start Date*: 2009-04-17
    Sponsor Name:Tibotec Pharmaceuticals
    Full Title: An open-label, Proof-of-Concept trial in treatment-naïve HIV-1- infected subjects to evaluate the antiviral activity of a single intramuscular dosing of TMC278LA as monotherapy.
    Medical condition: HIV-1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2020-005059-19 Sponsor Protocol Number: C0921062 Start Date*: 2021-03-31
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3B, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF NIMENRIX® IN HEALTHY INFANTS, GIVEN AT 3 AND 12 MONTHS OF AGE
    Medical condition: Invasive Meningococcal Disease (IMD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10076062 Meningococcal immunization LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-005075-88 Sponsor Protocol Number: V110_08 Start Date*: 2014-12-15
    Sponsor Name:Novartis Pharma K.K
    Full Title: A Multi-center, Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Doses of Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1...
    Medical condition: Prophylaxis of A (H1N1) 2009 Swine Origin Pandemic Influenza
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-002275-28 Sponsor Protocol Number: 1237.19 Start Date*: 2014-11-18
    Sponsor Name:Boehringer Ingelheim Finland Ky
    Full Title: A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compar...
    Medical condition: chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) IT (Completed) SE (Completed) PT (Completed) DK (Completed) BE (Completed) NL (Completed) HU (Completed) GB (Completed) ES (Completed) AT (Completed) IE (Completed) LT (Completed) CZ (Completed) LV (Completed) SK (Completed) DE (Completed) SI (Completed) GR (Completed) BG (Completed) HR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-008190-58 Sponsor Protocol Number: TMC310911-TiDP21-C201 Start Date*: 2009-04-03
    Sponsor Name:Tibotec Pharmaceuticals
    Full Title: A Phase IIa, open-label, randomized trial in treatment-naïve HIV-1-infected subjects to determine the antiviral activity of 14 days of monotherapy with 4 different dose regimens of TMC310911 co-adm...
    Medical condition: HIV-1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016480-11 Sponsor Protocol Number: 2009HD/01 Start Date*: 2009-12-28
    Sponsor Name:P Pierre Dellamonica
    Full Title: “No Nuc, No Boost” : A phase 2 pilot study of simplification by Maraviroc-Raltegravir following 6 months of treatment with Maraviroc-Raltegravir-Tenofovir-Emtricitabine in naive patients infected b...
    Medical condition: HIV naïve patients, CCR5 tropism, with CD4 > 200/mm3 and HIV RNA < 100 000 copy/ml.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004760-37 Sponsor Protocol Number: NA Start Date*: 2015-12-23
    Sponsor Name:Riitta Veijola
    Full Title: Incretin-based therapy in non-symptomatic, early diagnosed type 1 diabetics
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10045228 Type I diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003405-26 Sponsor Protocol Number: NF1-EXCEL Start Date*: 2014-09-03
    Sponsor Name:Erasmus MC
    Full Title: The effect of Lamotrigine on cognitive deficits associated with Neurofibromatosis type 1: a phase II randomized controlled multi-centre trial (NF1-EXCEL)
    Medical condition: Neurofibromatosis type 1
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004850 10029270 Neurofibromatosis, type 1 (von Recklinghausen's disease) LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed) DK (Prematurely Ended) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001301-24 Sponsor Protocol Number: IIV-407 Start Date*: 2020-03-20
    Sponsor Name:National Institute for Public Health and the Environment (RIVM)
    Full Title: ‘Primary and booster meningococcal vaccination in Dutch elderly: study to investigate the immune response and determine functional antibodies after the tetravalent MenACWY-TT conjugate vaccine in t...
    Medical condition: The tetravelent MenACWY-TT vaccin administered in this study is used to prevent invasive disease caused by Meningococcal serogroup A, C, W and Y.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005903-11 Sponsor Protocol Number: C4591017 Start Date*: 2022-01-20
    Sponsor Name:BioNTech SE
    Full Title: A Phase 3, Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of The Vaccine Candidate BNT162b2 Against COVID-19 i...
    Medical condition: SARS-CoV-2 Infection
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-004907-22 Sponsor Protocol Number: AUG117150 Start Date*: 2016-08-03
    Sponsor Name:Medicines Development (Infectious Diseases)
    Full Title: A multicenter, open-label study to assess the efficacy and safety of potassium clavulanate/amoxicillin (CVA/AMPC 1:14 combination) in the treatment of [Japanese] children with acute bacterial rhin...
    Medical condition: Acute Bacterial Rhinosinusitis
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-003142-51 Sponsor Protocol Number: DCR-PH1-101 Start Date*: 2016-04-11
    Sponsor Name:Dicerna Pharmaceuticals, Inc.
    Full Title: A Phase 1 Study of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1)
    Medical condition: Primary Hyperoxaluria Type 1
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-003560-74 Sponsor Protocol Number: p2011-1 Start Date*: 2012-09-25
    Sponsor Name:Leiden University Medical Center
    Full Title: Effectiveness of Clonidine for the treatment of radicular pain: A randomized, double-blind and prospective study. (EFFOC study)
    Medical condition: Radicular lumbar pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001083-28 Sponsor Protocol Number: C0921003 Start Date*: 2013-08-19
    Sponsor Name:Pfizer Inc
    Full Title: A Phase III, randomised, open, controlled, multicentre, primary vaccination study to evaluate the immunogenicity and persistence of 1 and 2 doses of meningococcal conjugate vaccine MenACWY-TT in ...
    Medical condition: Meningococcal disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004862 10028911 Neisseria meningitidis infection NOS LLT
    21.0 100000004848 10070124 Neisseria meningitidis test positive LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 04 08:16:37 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA